三泰控股上半年扭虧為盈 預盈7000萬-8500萬元
格隆匯7月8日丨三泰控股(002312.SZ)披露2020年半年度業績預告,公司預計2020年1-6月歸屬於上市公司股東的淨利潤為7000萬元-8500萬元,而上年同期為虧損6271.94萬元,同比實現扭虧為盈。業績扭虧主要系並表磷化工業務增厚業績所致。
值得注意的是,公司於2020年5月披露公司聯營企業中郵智遞與豐巢科技重組相關事宜,該次重組預計將為公司帶來4.36億元投資收益。目前重組工作進展順利,重組完成後,公司將不再按權益法分攤中郵智遞產生的虧損,會計處理將調整為按照公允價值變動來計量。
根據目前重組工作推進進程,報告期未計入以上4.36億元投資收益,後續將根據重組工作進展計入相應期間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.